Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMN 290
- Development stage
- Discontinued
- Lead developer
- BioMarin
- Modality
- Small Molecules
01
Overview
BMN 290 is a selective chromatin modulation therapy, specifically a histone deacetylase inhibitor, designed to increase frataxin expression. It is being developed for the treatment of Friedreich's ataxia (FA), a rare autosomal recessive disorder causing progressive neurological and cardiac decline.
02
Targets
HDAC (HDAC family)
Beyond the preview
Go deeper on BMN 290.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMN 290.